Mikhail Kosiborod discusses the CVD-REAL 2 study - Lower Risk of Cardiovascular Events and Death Associated With Initiation of SGLT-2 Inhibitors Versus Other Glucose Lowering Drugs.

Filmed on-site at the American College of Cardiology congress 2018 in Orlando, USA.